No Data
No Data
What You Can Learn From Luye Pharma Group Ltd.'s (HKG:2186) P/E
Luye Pharma Group to Divest 34.8% Stake in Shenzhen Unit
Luye Pharma: Proceeds From Investment to Be Used for Development of Group's Oncology Business
Luye Pharma (02186.HK): Investors are planning to invest up to RMB 1.6 billion in Luye Pharma Shenzhen.
On July 23, Gelunhui announced that on July 22, 2024, investors and sellers (Kanghai Medicine, Hong Kong Luye, and Fengmao Group collectively) and signatories of the agreement (the Company, Shenzhen Luye, Nanjing Luye, Yantai Luye, Shandong Luye, and Mr. Liu Dianbo) entered into an investment agreement. Accordingly, the investors conditionally agreed to invest up to RMB 1.6 billion in Shenzhen Luye (a subsidiary of Luye Pharmaceutical (Shenzhen) Co., Ltd.) and the investment will be implemented in several steps. Upon completion of the investment, the investors will hold a total of 3% of Shenzhen Luye.
Express News | Luye Pharma - Shenzhen Luye Private Equity Investment Fund Partnership to Make an Investment of up to RMB1,600 Mln in Luye Pharma (Shenzhen
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
No Data